Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Everolimus (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PACS11UNIRAD; UNIRAD
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 1931.
- 02 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2021.